Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Depreciation and Depletion (2016 - 2017)

Historic Depreciation and Depletion for CytomX Therapeutics (CTMX) over the last 2 years, with Q4 2017 value amounting to $400000.0.

  • CytomX Therapeutics' Depreciation and Depletion fell 2000.0% to $400000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2024, which is 2000.0% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Depreciation and Depletion of $400000.0 as of Q4 2017, which was down 2000.0% from $368000.0 recorded in Q3 2017.
  • In the past 5 years, CytomX Therapeutics' Depreciation and Depletion registered a high of $500000.0 during Q4 2016, and its lowest value of $368000.0 during Q3 2017.